Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Pulmatrix, Inc. (formerly traded on Nasdaq under the ticker PULM) is a clinical-stage biopharmaceutical company focused on the discovery and development of inhaled therapies for respiratory diseases. The company operates within the biotechnology and pharmaceutical research and development industries, with an emphasis on pulmonary drug delivery. Pulmatrix’s core value proposition has historically centered on its proprietary iSPERSE™ dry powder inhalation technology, designed to improve drug delivery efficiency to the lungs using lower doses and simpler inhaler devices.
The company’s primary programs have targeted conditions such as pulmonary fibrosis, pulmonary hypertension, and other serious lung diseases with unmet medical needs. Pulmatrix was founded in 2015 as a spin-out from academic research conducted at Harvard University, and it became a publicly traded company in 2016. Over time, the company progressed multiple assets into clinical development; however, its operating history has been marked by capital constraints, program reprioritizations, and strategic restructuring. Public disclosures indicate that Pulmatrix filed for Chapter 11 bankruptcy protection in 2023, and the continuity of its operations as an independent going concern beyond that point is not fully verifiable based on available public sources.
Business Operations
Pulmatrix’s historical operations were organized around a single operating segment focused on inhaled therapeutics development. Revenue generation was not based on product sales but instead depended on equity financings, grants, and, to a limited extent, collaboration or licensing arrangements. Key development-stage assets included inhaled formulations of treprostinil and other small-molecule therapies leveraging the iSPERSE™ platform.
The company did not maintain commercial manufacturing or sales infrastructure and relied on third-party contract research organizations and manufacturers for clinical trials and production. Pulmatrix’s operations were primarily domestic, with clinical trials and research activities conducted in the United States, while certain formulation development and manufacturing activities involved international vendors. There is no conclusive public evidence of ongoing major partnerships or joint ventures following the bankruptcy filing.
Strategic Position & Investments
Strategically, Pulmatrix positioned itself as a technology-driven platform company seeking to partner or out-license its inhalation technology and late-stage assets to larger pharmaceutical companies. Growth initiatives prior to restructuring focused on advancing lead candidates through clinical milestones to increase partnering or acquisition potential. The company periodically evaluated strategic alternatives, including asset sales and mergers.
Public filings indicate that Pulmatrix explored transactions involving the sale or transfer of certain intellectual property and development programs as part of its restructuring process. Specific outcomes of these efforts, including the ultimate ownership of iSPERSE™-related assets, are not consistently reported across public sources. Data inconclusive based on available public sources regarding the company’s current investment activities or control of operating subsidiaries post-bankruptcy.
Geographic Footprint
Pulmatrix was headquartered in the United States, with its principal executive offices historically located in Massachusetts. Its operational footprint was concentrated in North America, reflecting its focus on U.S.-based research, regulatory engagement with the U.S. Food and Drug Administration, and domestic clinical trial activity.
International exposure was limited and primarily indirect, arising from the use of overseas contract manufacturers or service providers. The company did not report material commercial operations, offices, or revenue-generating activities outside the United States.
Leadership & Governance
Pulmatrix was founded by academic and industry scientists, including David Edwards and Robert Langer, whose research contributed to the development of the company’s core inhalation technology. Over its operating history, the company experienced multiple leadership transitions aligned with shifts in strategic focus and financial condition. Governance was overseen by a board of directors with experience in biotechnology, drug development, and capital markets.
Key executives reported in public filings prior to restructuring included:
- Robert M. Clarke – President and Chief Executive Officer
- Eric L. Lonnstrom – Chief Financial Officer
- Thomas J. McGinn – Chief Operating Officer
- Dennis McWilliams – Chairman of the Board
Following the Chapter 11 process, the status of executive leadership and board composition is not consistently disclosed across public sources. Data inconclusive based on available public sources regarding current governance structure.